iSpecimen Inc.
ISPCHealthcareNASDAQDiagnostics & Research · Last scanned Oct 26, 2026
Scan Results
Daily timeframeiSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. At a $2.1M market cap, iSpecimen Inc. ranks as a micro-cap company within healthcare. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them.
Market Cap
$2.1M
Beta
1.65
P/E (TTM)
—
P/E (Fwd)
-1.03
EPS (TTM)
$-52.98
EPS (Fwd)
$-0.79
ROE
-968.5%
ROA
-87.7%
Cash
$4.4M
Total Debt
$240,903
Free CF
-$5.6M
52W Change
-97.5%
Annual Financials
Cash vs Debt
Where ISPC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ISPC finished 70.74% below its 150-day moving average ($3.11) and 83.09% below its 200-day moving average ($5.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ISPC overbought or oversold?
At the October 20, 2026 close, ISPC's RSI(14) was 19.2, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $4.4M in cash comfortably exceeding the $241K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$5.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -968.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $10.4M (2022) to $1.9M (2025), a 81% decline worth watching.
With a beta above 1.5, ISPC tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, ISPC has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence iSpecimen Inc.'s trajectory.